Literature DB >> 2493440

Lactivicin, a naturally occurring non-beta-lactam antibiotic having beta-lactam-like action: biological activities and mode of action.

Y Nozaki1, N Katayama, S Harada, H Ono, H Okazaki.   

Abstract

Lactivicin is moderately active against a wide range of Gram-negative bacteria and highly active against Gram-positive bacteria. It shows various biological activities commonly observed with beta-lactam antibiotics, such as higher activity against beta-lactam hypersensitive mutants than against their parents, sensitivity to beta-lactamases, inhibitory activity against beta-lactamases and ability to induce beta-lactamase activity. The primary lethal target of lactivicin in Escherichia coli is highly likely to be penicillin-binding protein (PBP) 1; lactivicin strongly lysed E. coli cells with induction of spheroplasts at its MIC, and showed high affinity for PBPs 1A and 1B. At concentrations above x 5 MIC, however, lactivicin dominantly exhibited secondary antibacterial action possibly owing to inhibition of crucial SH proteins engaged in the fundamental membrane functions. In contrast, against Bacillus subtilis, lactivicin showed the typical beta-lactam action under a wide range of concentrations. It showed high affinity for PBPs 1, 2 and 4, the possible lethal targets of beta-lactam antibiotics in this organism. In conclusion, lactivicin is the first non-beta-lactam antibiotic showing beta-lactam action through binding to PBPs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2493440     DOI: 10.7164/antibiotics.42.84

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  8 in total

Review 1.  Morphological and ultrastructural changes in bacterial cells as an indicator of antibacterial mechanism of action.

Authors:  T P Tim Cushnie; Noëlle H O'Driscoll; Andrew J Lamb
Journal:  Cell Mol Life Sci       Date:  2016-07-08       Impact factor: 9.261

2.  Evidence of an Unidentified Extracellular Heat-Stable Factor Produced by Lysobacter enzymogenes (OH11) that Degrade Fusarium graminearum PH1 Hyphae.

Authors:  Benard Omondi Odhiambo; Gaoge Xu; Guoliang Qian; Fengquan Liu
Journal:  Curr Microbiol       Date:  2017-02-17       Impact factor: 2.188

Review 3.  Bioactive natural products from Lysobacter.

Authors:  Yunxuan Xie; Stephen Wright; Yuemao Shen; Liangcheng Du
Journal:  Nat Prod Rep       Date:  2012-11       Impact factor: 13.423

4.  Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates.

Authors:  Karina Calvopiña; Klaus-Daniel Umland; Anna M Rydzik; Philip Hinchliffe; Jürgen Brem; James Spencer; Christopher J Schofield; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

5.  Structural basis of the inhibition of class A beta-lactamases and penicillin-binding proteins by 6-beta-iodopenicillanate.

Authors:  Eric Sauvage; Astrid Zervosen; Georges Dive; Raphael Herman; Ana Amoroso; Bernard Joris; Eveline Fonzé; Rex F Pratt; André Luxen; Paulette Charlier; Frédéric Kerff
Journal:  J Am Chem Soc       Date:  2009-10-28       Impact factor: 15.419

6.  Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibition.

Authors:  Hwanho Choi; Robert S Paton; Hwangseo Park; Christopher J Schofield
Journal:  Org Biomol Chem       Date:  2016-04-26       Impact factor: 3.876

Review 7.  Development of new drugs for an old target: the penicillin binding proteins.

Authors:  Astrid Zervosen; Eric Sauvage; Jean-Marie Frère; Paulette Charlier; André Luxen
Journal:  Molecules       Date:  2012-10-24       Impact factor: 4.411

Review 8.  A Review of the Pharmacological Activities and Recent Synthetic Advances of γ-Butyrolactones.

Authors:  Joonseong Hur; Jaebong Jang; Jaehoon Sim
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.